The most common neurological diseases cost the US $789bn in 2014, but as the elderly population continues to outpace younger generations in size, this number is projected to grow substantially.
According to the report by the American Neurological Association (ANA), neurological diseases affect an estimated 100m Americans per year, with the cost of dementia and stroke expected to exceed $600bn by 2030.
To address the challenges of clinical research in neurodegenerative diseases, the Morrisville, NC-based contract research organization (CRO) Worldwide Clinical Trials has announced a partnership with Datavant aimed at enhancing clinical trials methodologies and algorithms.
The partnership will enable the CRO to use Datavant’s software, which provides a holistic view of anonymous datasets by combining multiple data layers into a single de-identified dataset.
The companies will focus on understanding why neurodegenerative disease clinical trials fail, the ability of real-world evidence and big data to improve clinical trial conduct, and opportunities to use digital technology the prolonged trial monitoring required by these studies.
Initially, Worldwide and Datavant will design a high-profile pilot study combining traditional clinical operations with external data assets.
Earlier this year, Worldwide acquired Continuum Clinical’s Late Stage research practice following the increase in demand for real-world evidence. The CRO also has established a pediatric center of excellence to address the unique challenge posed by conducting research in children.